Microcalcifications Drive Breast Cancer Occurrence and Development by Macrophage-Mediated Epithelial to Mesenchymal Transition.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
11 Nov 2019
Historique:
received: 08 10 2019
revised: 08 11 2019
accepted: 09 11 2019
entrez: 14 11 2019
pubmed: 14 11 2019
medline: 1 4 2020
Statut: epublish

Résumé

This study aims to investigate: (a) the putative association between the presence of microcalcifications and the expression of both epithelial-to-mesenchymal transition and bone biomarkers, (b) the role of microcalcifications in the breast osteoblast-like cells (BOLCs) formation, and (c) the association between microcalcification composition and breast cancer progression. We collected 174 biopsies on which we performed immunohistochemical and ultrastructural analysis. In vitro experiments were performed to demonstrate the relationship among microcalcification, BOLCs development, and breast cancer occurrence. Ex vivo investigations demonstrated the significant increase of breast osteoblast-like cells in breast lesions with microcalcifications with respect to those without microcalcifications. In vitro data displayed that in the presence of calcium oxalate and activated monocytes, breast cancer cells undergo epithelial to mesenchymal transition. Also, in this condition, cells acquired an osteoblast phenotype, thus producing hydroxyapatite. To further confirm in vitro data, we studied 15 benign lesions with microcalcification from patients that developed a malignant condition in the same breast quadrant. Immunohistochemical analysis showed macrophages' polarization in benign lesions with calcium oxalate. Altogether, our data shed new light about the role of microcalcifications in breast cancer occurrence and progression.

Sections du résumé

BACKGROUND BACKGROUND
This study aims to investigate: (a) the putative association between the presence of microcalcifications and the expression of both epithelial-to-mesenchymal transition and bone biomarkers, (b) the role of microcalcifications in the breast osteoblast-like cells (BOLCs) formation, and (c) the association between microcalcification composition and breast cancer progression.
METHODS METHODS
We collected 174 biopsies on which we performed immunohistochemical and ultrastructural analysis. In vitro experiments were performed to demonstrate the relationship among microcalcification, BOLCs development, and breast cancer occurrence. Ex vivo investigations demonstrated the significant increase of breast osteoblast-like cells in breast lesions with microcalcifications with respect to those without microcalcifications.
RESULTS RESULTS
In vitro data displayed that in the presence of calcium oxalate and activated monocytes, breast cancer cells undergo epithelial to mesenchymal transition. Also, in this condition, cells acquired an osteoblast phenotype, thus producing hydroxyapatite. To further confirm in vitro data, we studied 15 benign lesions with microcalcification from patients that developed a malignant condition in the same breast quadrant. Immunohistochemical analysis showed macrophages' polarization in benign lesions with calcium oxalate.
CONCLUSIONS CONCLUSIONS
Altogether, our data shed new light about the role of microcalcifications in breast cancer occurrence and progression.

Identifiants

pubmed: 31718020
pii: ijms20225633
doi: 10.3390/ijms20225633
pmc: PMC6888678
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Breast Cancer Res Treat. 2019 Feb;173(3):751-752
pubmed: 30448898
Clin Breast Cancer. 2018 Aug;18(4):e659-e669
pubmed: 29306659
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Cell Biochem Biophys. 2013;67(3):1207-15
pubmed: 23700163
Adv Med Sci. 2017 Mar;62(1):78-82
pubmed: 28189947
Future Oncol. 2018 Dec;14(30):3097-3099
pubmed: 30411977
J Surg Oncol. 2017 Apr;115(5):517-522
pubmed: 28194807
Arch Biochem Biophys. 2008 May 15;473(2):139-46
pubmed: 18395508
Breast Cancer Res Treat. 2013 Feb;138(1):47-57
pubmed: 23338761
PLoS One. 2012;7(7):e41679
pubmed: 22911843
J Bone Miner Res. 2017 Jun;32(6):1297-1308
pubmed: 28177161
J Mech Behav Biomed Mater. 2014 Aug;36:12-20
pubmed: 24786380
J Pathol Clin Res. 2016 Jan 15;2(1):32-40
pubmed: 27499914
Br J Cancer. 2018 Oct;119(9):1129-1132
pubmed: 30327566
Clin Obstet Gynecol. 2016 Dec;59(4):688-709
pubmed: 27741212
Breast Cancer Res Treat. 2005 Dec;94(3):225-35
pubmed: 16258702
Hum Pathol. 1984 Sep;15(9):880-9
pubmed: 6469237
Front Immunol. 2018 Mar 05;9:417
pubmed: 29556234
J Oncol. 2019 Apr 10;2019:2087983
pubmed: 31093281
Eur J Histochem. 2018 Mar 15;62(1):2841
pubmed: 29569878
Eur J Histochem. 2014 Sep 12;58(3):2403
pubmed: 25308844
Future Oncol. 2018 Jan;14(1):9-11
pubmed: 29219614
J Mammary Gland Biol Neoplasia. 2018 Jun;23(1-2):89-99
pubmed: 29744755
Calcif Tissue Int. 2013 Oct;93(4):348-54
pubmed: 23334303
Breast J. 2019 Sep;25(5):1034-1036
pubmed: 31237740
Int J Biol Sci. 2012;8(2):272-88
pubmed: 22298955
J Med Screen. 2018 Jun;25(2):82-87
pubmed: 28691862
J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):181-7
pubmed: 16025224
Urol Oncol. 2019 May;37(5):297.e19-297.e31
pubmed: 30827759
Biofactors. 2011 Mar-Apr;37(2):75-82
pubmed: 21488130
J Pathol. 2016 Sep;240(1):50-60
pubmed: 27235726
Histopathology. 2016 Jan;68(1):57-69
pubmed: 26768029
Urol Res. 1990;18(1):17-20
pubmed: 2316067
Cell Death Dis. 2017 Oct 12;8(10):e3125
pubmed: 29022895
Breast Cancer Res Treat. 2011 Jul;128(1):259-66
pubmed: 21203901
N Am J Med Sci. 2011 May;3(5):227-33
pubmed: 22558599
Future Oncol. 2019 Feb;15(5):455-457
pubmed: 30618271
BMC Cancer. 2014 Apr 23;14:286
pubmed: 24758513
Cancer. 2004 Oct 15;101(8):1745-59
pubmed: 15386334
Muscles Ligaments Tendons J. 2017 May 10;7(1):200-201
pubmed: 28717630
Sci Rep. 2019 Jan 24;9(1):542
pubmed: 30679450

Auteurs

Manuel Scimeca (M)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.
San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy.
Fondazione Umberto Veronesi (FUV), Piazza Velasca 5, 20122 Milan, Italy.
Saint Camillus International University of Health Sciences, Via di Sant'Alessandro, 8, 00131 Rome, Italy.

Rita Bonfiglio (R)

Department of Experimental Medicine, University "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

Erika Menichini (E)

Department of Experimental Medicine, University "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

Loredana Albonici (L)

Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", 00133 Rome, Italy.

Nicoletta Urbano (N)

Nuclear Medicine, Policlinico "Tor Vergata", 00133 Rome, Italy.

Maria Teresa De Caro (MT)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

Alessandro Mauriello (A)

Department of Experimental Medicine, University "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

Orazio Schillaci (O)

Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, 86077 Pozzilli, Italy.

Alessandra Gambacurta (A)

Department of Experimental Medicine, University "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

Elena Bonanno (E)

Department of Experimental Medicine, University "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.
"Diagnostica Medica" and "Villa dei Platani", 83100 Avellino, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH